Thyroid cancer, malignant (ICD10 C75): combined sexes
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
73.9% |
82.1% |
84.7% |
85.7% |
||||||||
|
(unstandardized) |
(66.7-80.3%) |
(76.9-86.6%) |
(78.7-89.4%) |
(80.5-90.0%) |
||||||||
|
all 15-99 |
70.3% |
73.4% |
76.1% |
77.2% |
75.8% |
83.2% |
||||||
|
(age-standardized)# |
(57.9-80.7%) |
(62.9-82.4%) |
(60.4-87.0%) |
(63.0-87.1%) |
(69.3-82.9%) |
(80.9-85.6%) |
||||||
|
15-44 |
100.0% |
100.0% |
96.8% |
98.0% |
||||||||
|
- |
- |
(90.6-99.0%) |
(92.9-99.5%) |
|||||||||
|
45-54 |
83.4% |
89.8% |
85.0% |
90.2% |
||||||||
|
(68.9-91.8%) |
(79.1-95.4%) |
(62.5-94.8%) |
(75.2-96.6%) |
|||||||||
|
55-64 |
73.7% |
76.6% |
75.4% |
77.6% |
||||||||
|
(52.58-87.2%) |
(61.8-86.6%) |
(55.9-88.0%) |
(59.7-88.9%) |
|||||||||
|
65-74 |
42.9% |
51.1% |
69.1% |
67.4% |
||||||||
|
(26.6-59.3%) |
(35.4-65.8%) |
(52.4-82.0%) |
(48.0-82.3%) |
|||||||||
|
75-99 |
29.0% |
27.2% |
35.3% |
33.4% |
||||||||
|
(13.6-49.1%) |
(12.8-45.2%) |
(16.6-57.4%) |
(16.3-53.6%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x28000, 45-54 x17000, 55-64 x21000, 65-74 x20000, 75-99 x14000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|